farma 2024 ets

通報

問題一覧

Not typical for Dextromethorphan:

possesses analgesic effect in antitussive doses

Drug with antitussive effect: 1) Caffeine 2) Codeine 3) Dextroamphetamine 4) Dextromethorphan 5) Dexmethylphenidate

2, 4

Typical for Omalizumab: 1) is a monoclonal antibody 2) is analog of interleukin-5 3) binds to human immunoglobulin E 4) activates eosinophils 5) limits the release of mediators of the allergic response

1, 3, 5

Not typical for Salmeterol: 1) is a short-acting β2-agonist 2) stimulates β2-adrenergic receptors 3) used only in combination with an inhaled corticosteroids 4) used for quick relief of an acute asthma attack 5) has a long duration of action

1, 4

Not typical for Theophylline: 1) possesses anti-inflammatory activity 2) inhibits 5-lipoxygenase enzyme 3) used in chronic asthma 4) has narrow therapeutic window 5) used in status asthmaticus

2, 5

Mechanism of action of Digoxin: 1) markedly inhibits Na+/K+-ATPase 2) increases the Na+ concentration gradient 3) decreases the ability of the Na+/Ca2+-exchanger to move Ca2+ out of the cell 4) inhibited the ability of the myocyte to actively pump Na+ from the cell 5) markedly inducts Na+/K+-ATPase

1, 3, 4

Not typical for digitalis glycosides: 1) reduced sympathetic activity 2) vagal tone is enhanced 3) increase in end-diastolic volume 4) reduces peripheral resistance 5) increases conduction velocity

3, 5

Drugs with positive inotropic effect: 1) Diltiazem 2) Dobutamine 3) Digoxin 4) Dofetilide 5) Doxazosin

2, 3

Side effects of cardiac glycosides associated with hypokalemia: 1) Hypertension 2) Bronxoconstriction 3) Atrial arrhythmia 4) Slowing of AV conduction 5) Irritation at the injection site

3, 4

Mechanism of action of Milrinone:

inhibition of phosphodiesterase

Typical for Quinidine: 1) has cholinomimetic effect 2) binds to open and inactivated sodium channels 3) inhibits potassium channels 4) blocks α- and β-adrenergic receptors 5) blocks calcium channels

2, 3, 5

Typical for Procainamide: 1) acetylated in the liver to active metabolite 2) obtained from plant 3) contains iodine 4) is the prototype Class IA of antiarrhythmic drug 5) causes reversible lupus erythematosus-like syndrome

1, 4, 5

Not typical for Disopyramide:

shows effects of cholinomimetic activity

Not typical for Amiodarone: 1) Prolongs refractory period 2) Shorten refractory period 3) Blockade of K+ channels 4) Opening of K+ channels 5) Prolongs action potential duration 6) Shortens action potential duration

2, 4, 6

Typical for Carvedilol: 1) Selective blocks β1-adrenoreceptors 2) Blocks of α-adrenoreceptors 3) Non-selective blocks β-adrenoreceptors 4) Administration in cardiac failure 5) Contrindication in cardiac failure

2, 3, 4

Class IA antiarrhythmics: 1) Disopyramide 2) Procainamide 3) Flecainide 4) Propafenone 5) Lidocaine

1, 2

Not typical for Nitroglycerin:

increases the work of the heart

Specify relevance of antianginal drugs: I. β-Blockers II. Calcium-channel blockers III. Organic nitrates 1) Nicardipine, Nifedipine 2) Isosorbide mononitrate, Nitroglycerin 3) Metoprolol, Propranolol

I – 3; II – 1; III – 2

Antianginal effect of β-adrenergic-blocking agents does not include:

decrease vessels tone

Effects typical to angiotesine-converting enzyme inhibitors: 1) reducing peripheral vascular resistance 2) increased sodium and water retention 3) increased the secretion of aldosterone 4) increased the production of nitric oxide and of prostacyclin 5) decreased angiotensin II and increase bradykinin levels

1, 4, 5

Common adverse effects of angiotensin-converting enzyme inhibitors: 1) lupus erythematosus-like syndrome 2) dry cough 3) hypertrophic gingivitis 4) hypotension 5) hyperkalemia

2, 4, 5

Reason of hypotensive action of angiotesine-converting enzyme inhibitors: 1) decrease in bradykinin metabolism 2) increase in bradykinin metabolism 3) increase in prostacyclin synthesis 4) decrease in prostacyclin synthesis 5) increase in NO level 6) decrease in NO level

1, 3, 5

Typical for Losartan: 1) increase bradykinin levels 2) produce arteriolar and venous dilation 3) increase the nephrotoxicity 4) lead to angioedema 5) block aldosterone secretion

2, 5

Typical for angiotensin II-receptor blockers: 1) lowering blood pressure 2) increases risks of cough 3) decreasing salt and water retention 4) improves aldosterone secretion 5) blocks degradation of bradykinin

1, 3

Influence of Diltiazem on cardiovascular system:

relaxes both the heart muscle and vascular smooth muscle cells

Therapeutic uses of calcium-channel blockers: 1) sick sinus syndrome 2) supraventricular bradyarrhythmia 3) hypertension 4) angina 5) acute myocardial infarction

3, 4

Not typical for Spironolaсton:

uses in Addison disease

Drugs used to treat peptic ulcers disease: 1) Granisetron, Ondansetron 2) Omeprazole, Pantoprazole 3) Aprepitant, Meclizine 4) Bismuth subsalicylate, Sucralfate 5) Aluminum hydroxide, Magnesium hydroxide

2, 4, 5

Not typical for Omeprazole: 1) blockade H2-histamine receptors 2) blockade proton pump 3) lowering vitamin B12 4) use in Zollinger-Ellison syndrome 5) blockade D2 dopamine receptors

1, 5

Antihistamine drug with antiemetic activity:

Meclizine

Action, typical for Granisetron:

antiserotoninergic

Mechanism of antiemetic action of Palonosetron:

block of 5HT3-serotonin receptors

Antiemetic effect of Meclizine associated with:

antihistaminergic action

Basic receptors associated with antiemetic action of Cyclizine:

H1-histamin

Determine the conformity of antiemetic drugs: I. Aprepitant II. Dimenhydrinate III. Ondansetron a) blocks 5-HT3 receptors b) blocks NK1-neurokinin receptors c) blocks H1-histamin receptors

I-b; II-c; III-a

Determine the conformity of antiemetic drugs: I. Meclizine II. Metoclopramide III. Tropisetron IV. Aprepitant a) NK1-neurokinin receptor b) H1 receptor c) D2 receptor d) 5HT3 receptor

I-b; II-c; III-d; IV-a

Drug decreasing intestine motility:

Loperamide

Determine the conformity of antidiarrheal drugs: I. Antimotility agents II. Adsorbents III. Agents that modify fluid and electrolyte transport a) Bismuth subsalicylate b) Aluminum hydroxide c) Diphenoxylate

I-c; II-b; III-a

Determine the conformity: I. Antidiarrheal drugs II. Laxatives a) Bismuth subsalicylate b) Aluminum hydroxide c) Magnesium hydroxide d) Methylcellulose I II

a, b, d c, d

Decrease motility of the gastrointestinal tract: 1) Atropine 2) Diphenoxylate 3) Senna 4) Loperamide 5) Bisacodyl

1, 2, 4

Mechanism of antiemetic action of Aprepitant:

selective blocks NK1-neurokinin receptors

Typical for Aprepitant: 1) converting to active metabolite 2) blockade of prostaglandins 3) induction CYP3A4 4) blockade D2-dopamine receptors 5) blockade NK1-neurokinin receptors

3, 5

Typical for Lepirudin: 1) obtained from lungs of bovine animals 2) direct thrombin antagonist 3) blockade of the thrombogenic activity of thrombin 4) little effect on platelet aggregation 5) indirect anticoagulant

2, 3, 4

Typical for Protamine sulfate: 1) antagonist of warfarin 2) antagonist of heparin 3) positively charged 4) antagonist of phytonadione 5) negatively charged

2, 3

Specify relevance: I. Abciximab II. Dipyridamole 1) antiplatelet action 2) monoclonal antibody 3) coronary vasodilator 4) glycoprotein GP IIb/IIIa receptor blocker 5) inhibitor cyclic nucleotide phosphodiesterase I II

1, 2, 4 1, 3, 5

Not typical for Warfarin: 1) anticoagulant effect observed after 8-12 hours 2) directly anticoagulant 3) oral anticoagulant 4) anticoagulant effect observed until 8-12 hours 5) vitamin K antagonist

2, 4

Anticoagulants is vitamin K antagonists: 1) Warfarin 2) Enoxaparin 3) Dicumarol 4) Heparin 5) Lepirudin

1, 3

Use of Corticotropin: 1) treatment of multiple sclerosis 2) diagnostic of primary adrenal insufficiency 3) differentiating secondary adrenal insufficiency 4) differentiating secondary acromegaly 5) treatment of Cushing syndrome

1, 2, 3

Determine the conformity of treatment: I. Hypothyroidism II. Hyperthyroidism a) Methimazole b) Levothyroxine c) Propylthiouracil

I – b; II – a, c

Determine the conformity of oral antidiabetic drugs: I. Sulfonylureas II. Biguanides a) Metformin b) Glyburide c) Glipizide

I – b, c; II – a

Dr.Fatimə Hüseynova Alman Dili sualları 1-50

samnet net · 50問 · 2年前

Dr.Fatimə Hüseynova Alman Dili sualları 1-50

50問 • 2年前

Dr. Fatimə Hüseynova Alman dili sualları 51-100

samnet net · 56問 · 2年前

Dr. Fatimə Hüseynova Alman dili sualları 51-100

56問 • 2年前

Dr.Fatimə Hüseynova Alman Dili sualları 101-150

samnet net · 50問 · 2年前

Dr.Fatimə Hüseynova Alman Dili sualları 101-150

50問 • 2年前

Dr. Fatimə Hüseynova Alman dili sualları 151-200

samnet net · 52問 · 2年前

Dr. Fatimə Hüseynova Alman dili sualları 151-200

52問 • 2年前

Histology Questions 1-100

samnet net · 76問 · 2年前

Histology Questions 1-100

76問 • 2年前

Histology Questions 101-200

samnet net · 84問 · 2年前

Histology Questions 101-200

84問 • 2年前

Histology Questions 201-300

samnet net · 81問 · 2年前

Histology Questions 201-300

81問 • 2年前

Histology Questions 301-395

samnet net · 79問 · 2年前

Histology Questions 301-395

79問 • 2年前

Histology 1

samnet net · 40問 · 3年前

Histology 1

40問 • 3年前

Micro 20 soru

samnet net · 17問 · 2年前

Micro 20 soru

17問 • 2年前

fizyoloji chapter 3 Ğerip

samnet net · 132問 · 2年前

fizyoloji chapter 3 Ğerip

132問 • 2年前

HİSTOLOGY 2 MİDTERM

HİSTOLOGY 2 MİDTERM

gıdalanma 31-60

samnet net · 31問 · 2年前

gıdalanma 31-60

31問 • 2年前

microbiology ETS 1-100

samnet net · 99問 · 2年前

microbiology ETS 1-100

99問 • 2年前

microbiology 101-200

samnet net · 93問 · 2年前

microbiology 101-200

93問 • 2年前

microbiology 201-290

samnet net · 84問 · 2年前

microbiology 201-290

84問 • 2年前

ictimai son ETS

ictimai son ETS

histo 2 final ets

samnet net · 110問 · 2年前

histo 2 final ets

110問 • 2年前

fizyo ets final 100

fizyo ets final 100

biyokimya 1-111

samnet net · 111問 · 2年前

biyokimya 1-111

111問 • 2年前

biyokimya ets final

biyokimya ets final

171-207

samnet net · 37問 · 2年前

171-207

37問 • 2年前

patfiz 32-70

samnet net · 36問 · 1年前

patfiz 32-70

36問 • 1年前

pato genel

samnet net · 112問 · 1年前

pato genel

112問 • 1年前

pato

samnet net · 26問 · 1年前

pato

26問 • 1年前

epidem61-90

samnet net · 30問 · 1年前

epidem61-90

30問 • 1年前

biyofizik 65-80

samnet net · 15問 · 1年前

biyofizik 65-80

15問 • 1年前

micro 2 finally ets

micro 2 finally ets

normal physiology finally

samnet net · 99問 · 1年前

normal physiology finally

99問 • 1年前

Tekamül Genetikası

Tekamül Genetikası

Farma final ets

Farma final ets

ETS biophysics 125

samnet net · 125問 · 1年前

ETS biophysics 125

125問 • 1年前

patfiz ets

patfiz ets

epidemiology ets

epidemiology ets

Patfiz 1-48

samnet net · 47問 · 1年前

Patfiz 1-48

47問 • 1年前

Parazitoloji 1-50

samnet net · 49問 · 1年前

Parazitoloji 1-50

49問 • 1年前

takıldıklarım

samnet net · 35問 · 1年前

takıldıklarım

35問 • 1年前

yeni

samnet net · 33問 · 1年前

yeni

33問 • 1年前

radyo 1-40

samnet net · 71問 · 1年前

radyo 1-40

71問 • 1年前

derma 31-60

samnet net · 30問 · 1年前

derma 31-60

30問 • 1年前

Farma ets

samnet net · 48問 · 1年前

Farma ets

48問 • 1年前

Radyo ets

Radyo ets

radyo 101-200

radyo 101-200

Radyo 201-300

samnet net · 102問 · 1年前

Radyo 201-300

102問 • 1年前

Radyo ETS 41-100

samnet net · 60問 · 1年前

Radyo ETS 41-100

60問 • 1年前

Patfiz ETS 2025

Patfiz ETS 2025

patfiz 2024

patfiz 2024

Patfiz ilk50

Patfiz ilk50

Parazitoloji ETS

Parazitoloji ETS

Parazit final

Parazit final

Parazit final 1-100

Parazit final 1-100

parazit 101-200

parazit 101-200

Parazit 201-244

samnet net · 44問 · 1年前

Parazit 201-244

44問 • 1年前

Parazitoloji 1-50

Parazitoloji 1-50

Genel cerrahi ETS 2025

Genel cerrahi ETS 2025

Genel cerrahi Final 1-100

Genel cerrahi Final 1-100

Genel cerrahi Final 101-200

Genel cerrahi Final 101-200

Genel cerrahi Final 201-300

Genel cerrahi Final 201-300

Genel cerrahi Final 301-400

Genel cerrahi Final 301-400

Genel cerrahi Final 401-468

samnet net · 68問 · 1年前

Genel cerrahi Final 401-468

68問 • 1年前

Patoloji Anatomisi ETS

Patoloji Anatomisi ETS

Patfiz 1-136

Patfiz 1-136

Dermatoloji ETS

Dermatoloji ETS

Dermatoloji 1-100

Dermatoloji 1-100

Dermatoloji 101-200

Dermatoloji 101-200

Dermatoloji 201-284

samnet net · 84問 · 1年前

Dermatoloji 201-284

84問 • 1年前

Derma ETS ilk50

Derma ETS ilk50